U.S. markets closed
  • S&P 500

    4,536.37
    +16.74 (+0.37%)
     
  • Dow 30

    35,609.93
    +152.62 (+0.43%)
     
  • Nasdaq

    15,121.68
    -7.41 (-0.05%)
     
  • Russell 2000

    2,288.41
    +12.49 (+0.55%)
     
  • Crude Oil

    84.25
    +1.29 (+1.55%)
     
  • Gold

    1,785.60
    +15.10 (+0.85%)
     
  • Silver

    24.42
    +0.53 (+2.23%)
     
  • EUR/USD

    1.1655
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    1.6360
    +0.0010 (+0.06%)
     
  • GBP/USD

    1.3826
    +0.0032 (+0.24%)
     
  • USD/JPY

    114.2760
    -0.0840 (-0.07%)
     
  • BTC-USD

    66,405.82
    +2,196.18 (+3.42%)
     
  • CMC Crypto 200

    1,549.16
    +68.36 (+4.62%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Why Acasti Pharma's Stock Is Trading Higher Today

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.

Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk.

The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia

Acasti Pharma shares were trading up 16.74% at 62 cents on Monday. The stock has a 52-week high of $3.08 and a 52-week low of 25 cents.

Latest Ratings for ACST

Jul 2020

B. Riley FBR

Upgrades

Neutral

Buy

May 2020

Aegis Capital

Maintains

Buy

Feb 2020

H.C. Wainwright

Maintains

Buy

View More Analyst Ratings for ACST
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.